Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 5 (2018)

Comparative study on formulation and evaluation of fast dissolving Glibenclamide tablets: Opportunity in drug delivery system

Author(s):
Shammi Akhter, Simom Hasan, Md. Mehdi Hasan and Dr. Hasan Mahamud Reza
Abstract:
Glibenclamide Tablets are used to lower blood sugar levels and are used in the treatment of late-onset diabetes (type II diabetes mellitus) in patients whose blood sugar is not controlled by diet alone and who are not suitable for insulin injections. The present work involves the formulation development, optimization and in-vitro evaluation of fast dissolving tablet containing Glibenclamide. All formulations were evaluated for characteristics such as hardness, friability, disintegration time and Dissolution rate. An effective, pleasant tasting formulation was found to have a good hardness of 3 kg/cm2, disintegration time of 27+1 seconds and in vitro drug release of not less than 95% within 30 minutes. The drug release was found to be comparable with the marketed dispersible tablet. our drug meets all the criteria mentioned above. specially formulation 5 is best among all the formulations. The purpose of above study was to develop tablet of Glibenclamide using direct compression technique. The tablets were prepared using lactose and magnesium stearate with two different level of disintegrant. The super-disintegrant used in the study was starch. The total five formulations were evaluated for weight variation, thickness, hardness, friability, content of uniformity, disintegration time and dissolution characteristics
Pages: 333-342  |  796 Views  87 Downloads
How to cite this article:
Shammi Akhter, Simom Hasan, Md. Mehdi Hasan, Dr. Hasan Mahamud Reza. Comparative study on formulation and evaluation of fast dissolving Glibenclamide tablets: Opportunity in drug delivery system. Pharma Innovation 2018;7(5):333-342.
The Pharma Innovation Journal